Actuate Therapeutics Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients, Showing Encouraging Results

Strategic Insights -

Actuate Therapeutics, a clinical-stage biopharmaceutical company, has announced the completion of the Phase 1 portion of its clinical study evaluating elraglusib monotherapy or in combination with other treatments in pediatric patients with refractory malignancies. The study, which enrolled ten patients with relapsed/refractory Ewing Sarcoma, has yielded promising results, with two patients achieving complete responses, and two patients experiencing durable stable disease.

Key Takeaways:

  • The study enrolled ten patients with relapsed/refractory Ewing Sarcoma, a notoriously difficult-to-treat cancer that affects children and young adults.
  • Two patients achieved complete responses, where their cancer was undetectable by CT and/or complete metabolic responses.
  • Two patients had durable stable disease, where their cancer did not progress, despite treatment.
  • A confirmed partial response was observed in one patient with a desmoplastic small-round-cell tumor (DSRCT), a rare type of sarcoma.
  • The study's results suggest that elraglusib may be a potential first-in-class therapy option for patients with relapsed/refractory Ewing Sarcoma, where few treatment options are available.
  • Actuate Therapeutics plans to initiate a Phase 2 trial of elraglusib in children, adolescents, and adults with relapsed/refractory Ewing Sarcoma, aiming to further investigate the drug's efficacy and safety.
  • The company is collaborating with key opinion leaders and consortiums to design the Phase 2 study, ensuring it aligns with patient needs and regulatory expectations.
  • The study's results are considered positive evidence of anti-tumor activity in a difficult-to-treat indication, and Actuate plans to further investigate elraglusib's ability to positively change patients' potential for successful treatment.

Statistics:

  • 10 patients were enrolled in the study.
  • 2 patients achieved complete responses.
  • 2 patients had durable stable disease.
  • 1 patient experienced a confirmed partial response.
  • The study's sample size specific to Ewing Sarcoma was small, with only 10 patients enrolled.
  • The study's findings suggest that elraglusib may have a potential role in treating relapsed/refractory Ewing Sarcoma, where few treatment options are available.

Sources:

  • Actuate Therapeutics. (2025, July 17). Actuate Therapeutics Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients. GlobeNewswire.
  • Actuate Therapeutics. (2024). Actuate Therapeutics Annual Report on Form 10-K.
  • SEC. (2025, March 13). Actuate Therapeutics, Inc. Form 10-K.
  • SEC. (2025, May 15). Actuate Therapeutics, Inc. Form 10-Q.